Abstract:Parkinson's disease (PD) is the second most common cause of neurodegeneration. Over the last two decades, various hypotheses have been proposed to explain the etiology of PD. Among these is the oxidant-antioxidant theory, which asserts that local and systemic oxidative damage triggered by reactive oxygen species and other free radicals may promote dopaminergic neuron degeneration. Excessive reactive oxygen species formation, one of the underlying causes of pathology in the course of PD has been evidenced by various studies showing that oxidized macromolecules including lipids, proteins, and nucleic acids accumulate in brain tissues of PD patients. DNA oxidation may produce various lesions in the course of PD. Mutations incurred as a result of DNA oxidation may further enhance reactive oxygen species production in the brains of PD patients, exacerbating neuronal loss due to defects in the mitochondrial electron transport chain, antioxidant depletion, and exposure to toxic oxidized dopamine. The protein products of SNCA, PRKN, PINK1, DJ1, and LRRK2 genes are associated with disrupted oxidoreductive homeostasis in PD. SNCA is the first gene linked with familial PD and is currently known to be affected by six mutations correlated with the disorder: A53T, A30P, E46K, G51D, H50Q and A53E. PRKN encodes Parkin, an E3 ubiquitin ligase which mediates the proteasome degradation of redundant and disordered proteins such as glycosylated α-synuclein. Over 100 mutations have been found among the 12 exons of PRKN. PINK1, a mitochondrial kinase highly expressed in the brain, may undergo loss of function mutations which constitute approximately 1–8% of early onset PD cases. More than 50 PD-promoting mutations have been found in PINK1. Mutations in DJ-1, a neuroprotective protein, are a rare cause of early onset PD and constitute only 1% of cases. Around 20 mutations have been found in DJ1 among PD patients thus far. Mutations in the LRRK2 gene are the most common known cause of familial autosomal dominant PD and sporadic PD. Treatment of PD patients, especially in the advanced stages of the disease, is very difficult. The first step in managing progressive PD is to optimize dopaminergic therapy by increasing the doses of dopamine agonists and L-dopa. The next step is the introduction of advanced therapies, such as deep brain stimulation. Genetic factors may influence the response to L-dopa and deep brain stimulation therapy and the regulation of oxidative stress. Consequently, research into minimally invasive surgical interventions, as well as therapies that target the underlying etiology of PD is warranted.

Physiological And Pathological Role Of Alpha-Synuclein In Parkinson'S Disease Through Iron Mediated Oxidative Stress; The Role Of A Putative Iron-Responsive Element

Physiological and Pathological Functions of Neuronal Hemoglobin: A Key Underappreciated Protein in Parkinson’s Disease

Iron-related Nigral Degeneration Influences Functional Topology Mediated by Striatal Dysfunction in Parkinson's Disease.

Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

Iron Deposition Leads to Neuronal Α-Synuclein Pathology by Inducing Autophagy Dysfunction.

Genetic Impacts on Nigral Iron Deposition in Parkinson's Disease: A Preliminary Quantitative Susceptibility Mapping Study.

Alpha-Synuclein Aggregation in Parkinson's Disease

Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron

Environmental pollutants and alpha-synuclein toxicity in Parkinson's disease

The Role of α-Synuclein Oligomers in Parkinson’s Disease

Different Iron Deposition Patterns in Early- and Middle-Late-onset Parkinson's Disease.

Hypoxia and Alpha-Synuclein: Inextricable Link Underlying the Pathologic Progression of Parkinson's Disease

Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson's Disease

Neuroinflammation and Oxidation/Nitration of Alpha-Synuclein Linked to Dopaminergic Neurodegeneration

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease

Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases

A crazy trio in Parkinson's disease: metabolism alteration, α-synuclein aggregation, and oxidative stress

[Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].

Oxidative stress factors in Parkinson’s disease

alpha-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease